Historical financial figures
Six-year summary
Not adj. pursuant to IFRS
Medivir Group 1, sek (000) 2007 2006 2005 2004 2003 2002
INCOME STATEMENT
Net sales 2 249,623 126,048 102,646 82,602 149,033 256,309
Change in work in progress and finished goods 0 0 0 0 2,330 2,996
Other turnover 3,840 3,287 2,211 2,505 1,252 112
Operating costs - 290,783 - 330,931 - 220,996 - 211,442 - 264,913 - 329,998
Operating profit - 37,320 - 201,596 - 116,139 - 126,335 - 112,298 - 70,581
Profit from financial investments 3 8,489 1,140 8,335 12,330 69,575 6,362
Profit after financial items 3 - 28,832 - 200,455 - 107,805 - 114,005 - 42,723 - 64,219
Full tax - 487 4,876 3,229 2,490 2,409 4,420
Profit after full tax - 29,318 - 195,580 - 104,576 - 111,515 - 40,314 - 59,799



07-12-31 06-12-31 05-12-31 04-12-31 03-12-31 02-12-31
BALANCE SHEET
Intangible fixed assets 936 1,390 9,052 10,927 10,712 37,110
Tangible fixed assets 35,878 33,361 81,708 80,732 40,154 109,420
Financial fixed assets 18,793 0 47 47 3,130 3,130
Inventories and current receivables 73,928 56,942 63,304 24,323 14,518 76,888
Liquid assets and short-term investments 4 329,330 195,066 301,875 440,569 239,174 143,856
Shareholders' equity 383,979 186,306 377,964 475,694 277,847 320,028
Deferred tax liability / provisions 0 0 2,039 2,519 0 3,672
Long-term liabilities, interest bearing 0 0 11,194 21,200 3,352 4,503
Current liabilities 74,887 100,452 66,827 59,702 26,489 42,201
Total assets 458,866 286,758 455,985 556,597 307,688 370,404
Capital employed 383,979 193,181 398,325 506,061 281,199 324,531

1) International Financial Reporting Standards (IFRS) apply for the financial years 2004-2007. Amounts for 2002-2003 are presented pursuant to the accounting principles Medivir applied for the financial year 2004. For a review of the accounting principles applied for the years 2002-2003, refer to the Annual Report 2004.

2) Net sales in 2007 mainly comprised three milestone payments totaling sek 182.3 m for HCV protease inhibitors from Tibotec Pharmaceuticals Ltd.

3) Gains from the divestment of the CCS group were included in financial investments in 2003.

4) The increase in liquid assets in 2007 and 2004 are due to factors including the new share issue effected by Medivir AB in the first quarter of 2007 and the second quarter of 2004.



Key-figures and definitions
Not adj. pursuant to IFRS
Medivir group 1 2007 2006 2005 2004 2003 2002
Operating margin, % - 15.0 - 159.9 - 113.1 - 152.9 - 75.4 - 27.5
Profit margin, % - 11.6 - 159.0 - 105.0 - 138.0 - 28.7 - 25.1
Debt gearing, multiple 0.00 0.04 0.05 0.06 0.0 0.0
Return on equity, % - 10.3 - 69.3 - 24.5 - 29.7 -13.5 - 17.6
Return on capital employed, % - 9.9 - 66.6 - 23.7 - 28.9 - 13.9 - 18.5
Return on total capital, % - 7.6 - 52.8 - 21.0 - 26.2 - 12.4 - 16.3
Equity ratio, % 83.7 65.0 82.9 85.5 90.3 86.4
Average number of shares, thousand 16,873 12,903 12,903 10,746 8,590 8,439
Number of shares, closing balance, thousand 20,844 12,903 12,903 12,903 8,590 8,590
Earnings per share, before and after dilution, sek 2 - 1.74 - 15.16 -8.10 - 10.38 - 4.69 - 7.09
Shareholders' equity per share,
before and after dilution, sek 2		 18.42 14.44 29.29 36.87 32.35 37.26
Net worth per share, before and after dilution, sek 2 18.42 14.44 29.29 36.87 32.96 37.81
Cash flow per share after investments, sek - 4.91 - 7.39 - 2.17 - 22.12 11.20 - 7.45
Cash flow per share after financing activity, sek 7.95 - 8.28 - 10.75 18.74 11.10 - 4.61
Dividend per share, sek 0 0 0 0 0 0
Number of outstanding warrants 970,000 676,995 886,995 646,895 449,900 513,400

Earnings per share, forecast for 2008, please refer to the Outlook section of the Director's Report in the Annual Report 2007.

1) International Financial Reporting Standards (IFRS) apply for the financial years 2004-2007. Amounts for 2002-2003 are presented pursuant to the accounting principles
Medivir applied for the financial year 2004. For a review of the accounting principles applied for the year 2002-2003, refer to the Annual Report 2004.

2) Pursuant to IAS 33, potential ordinary shares do not give rise to any dilution effects when their conversion to ordinary shares implies an improvement to earnings per share,
as would apply coincident with the conversion of Medivir's outstanding options.



Definitions

Average number of shares
The unweighted average number
of shares during the year.

Capital employed
Total assets less non interest-bearing liabilities including deferred tax liabilities.

Cash flow per share
Cash flow divided by the average number of shares.

Debt gearing
Interest-bearing liabilities divided
by shareholders' equity.

Earnings per share
Profit after financial items less full tax divided by the average number of shares.

Equity ratio
Shareholders' equity in relation to total assets.

Full tax
Tax on profit after financial items and deferred tax on change in untaxed reserves.

Net worth per share
Shareholders' equity plus, until 31 Dec 2004, hidden assets in listed equities less deferred tax, i.e. assets not included in ordinary operations, divided by the number of shares at the end of the period. Net worth does not include the value of research projects, patents, real estate, CCS' operations (divested 30 June 2003), etc.

Operating margin
Operating profit as a percentage
of net sales.

Profit margin
Profit after financial items as a
percentage of net sales.

 

Return on equity
Profit after financial items less full tax as a percentage of average shareholders' equity.

Return on capital employed
Profit after financial items plus financial costs as a percentage of average capital employed.

Return on total capital
Profit net of financial items plus financial costs as a percentage of average total assets.

Shareholders' equity
Taxed shareholders' equity plus 72% of untaxed reserves.

Shareholders' equity per share
Shareholders' equity divided by the number of shares at the end of the period.


Last Modified: 05/09/2008